Participating Faculty: The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Patient Management and Outcomes

Faculty

David Ginsberg, MD

Associate Professor of Clinical Urology

Department of Urology

Keck School of Medicine

University of Southern California

Los Angeles, California

Chief, Department of Urology

Rancho Los Amigos National Rehabilitation Center

Downey, California

William J. Cardarelli, PharmD

Director of Pharmacy Revenue and Supply

Atrius Health

Harvard Vanguard Medical Associates

Watertown, Massachusetts

Contributing Editorial Support

Elizabeth Paczolt, MD, FACNM

Medical Consultant

Churchville, Pennsylvania

This activity is supported by an educational grant from Allergan, Inc.

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

David Ginsberg, MD

Consultant or paid advisory board/honoraria: Allergan, Inc, American Medical Systems, and Pfizer

Lecture fees for speaking at the invitation of a commercial sponsor: Allergan, Inc

William J. Cardarelli, PharmD, and Elizabeth Paczolt, MD, FACNM, have no relevant financial relationships with commercial interests to disclose.

The American Journal of Managed Care

Publishing Staff—Jeff D. Prescott, PharmD, RPh; Kara Guarini, MS; and Ida Delmendo have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Office of Continuing Professional Education

Planning Staff—Judy V. Lum, MPA; David Heckard; Elena Beyzarov, PharmD; Donna W. Fausak; Ann C. Lichti, CCMEP; and Steve Lin, PharmD, RPh, have no relevant financial relationships with commercial interests to disclose.

University of Cincinnati

Planning Staff—Susan P. Tyler, MEd, CMP, CCMEP, has no relevant financial relationships with commercial interests to disclose.

Physician Reviewer—Rick Ricer, MD, has no relevant financial relationships with commercial interests to disclose.

This supplement to The American Journal of Managed Care is intended to provide an understanding of the pathophysiology of neurogenic bladder (NGB) and its impact on patient health and quality of life. The discussion will include an overview of appropriate diagnosis and assessment of patients with NGB/neurogenic detrusor overactivity and a review of roles, benefits, and risks of approved and emerging therapies. Also included is an analysis of economic and healthcare utilization impact associated with NGB and its consequences.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Download PDF: Participating Faculty: The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Patient Management and Outcomes